Article

Temporary, repeatable hyperopic correction

For patients with low to moderate hyperopia who may be risk-adverse for surgical correction, there is a low-cost, non-invasive, pain-free procedure of 2.5 seconds, said James J. Salz, MD.

New Orleans-For patients with low to moderate hyperopia who may be risk-adverse for surgical correction, there is a low-cost, non-invasive, pain-free procedure of 2.5 seconds, said James J. Salz, MD.

The patient will also have immediate vision improvement after noninvasive keratoplasty.

The catch for patients is also the bonus for practitioners: the effect is temporary, gradually fading, which, if the patient desires, can lead to multiple re-treatments.  

“The plan is to re-treat as they lose effect,” said Dr. Salz, clinical professor of ophthalmology, University of Southern California, Los Angeles.  

As an example, one patient was treated with noninvasive keratoplasty 10 times over 5 years. Many patients maintain good results up to 2 years, he said.

Although Dr. Salz’s clinical trial is temporarily on hold due to protocols surrounding an equipment change, the U.S clinical trial for correction of low to moderate hyperopia by noninvasive keratoplasy has looked at 10 eyes.

Of these, zero adverse events or statistically significant changes were reported in corrected distance visual acuity, astigmatism, IOP, corneal thickness, endothelial cell density, ocular aberrations, or corneal sensitivity. 

In terms of effectiveness, in post-primary treatment, the mean binocular uncorrected distance visual acuity was 20/25 or better; improvements were statistically significant through 24 months.

During noninvasive keratoplasty, the corneal epithelium is left intact, protected by a sapphire window, which acts as heat sink to protect from thermal damage.

 

 

 

For more articles in this issue of Ophthalmology Times Conference Brief click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.